Clinica Baviera
Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics in Spain and Europe. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics offers myopia, hyperopia, astigmatism, farsightedness, presbyopia, cataract, retinal, plastic surgery, pediatric ophthalmology, glaucoma, strabismus, cornea, neuro-ophthalmol… Read more
Clinica Baviera (CBAV) - Net Assets
Latest net assets as of September 2025: €97.36 Million EUR
Based on the latest financial reports, Clinica Baviera (CBAV) has net assets worth €97.36 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€228.01 Million) and total liabilities (€130.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €97.36 Million |
| % of Total Assets | 42.7% |
| Annual Growth Rate | 10.67% |
| 5-Year Change | 119.04% |
| 10-Year Change | 361.52% |
| Growth Volatility | 17.57 |
Clinica Baviera - Net Assets Trend (2005–2024)
This chart illustrates how Clinica Baviera's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Clinica Baviera (2005–2024)
The table below shows the annual net assets of Clinica Baviera from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €98.36 Million | +6.59% |
| 2023-12-31 | €92.28 Million | +34.97% |
| 2022-12-31 | €68.37 Million | +23.42% |
| 2021-12-31 | €55.39 Million | +23.36% |
| 2020-12-31 | €44.90 Million | +45.77% |
| 2019-12-31 | €30.80 Million | +7.09% |
| 2018-12-31 | €28.76 Million | +15.62% |
| 2017-12-31 | €24.88 Million | +33.94% |
| 2016-12-31 | €18.57 Million | -12.84% |
| 2015-12-31 | €21.31 Million | +5.49% |
| 2014-12-31 | €20.20 Million | -20.29% |
| 2013-12-31 | €25.35 Million | +21.52% |
| 2012-12-31 | €20.86 Million | -12.47% |
| 2011-12-31 | €23.83 Million | +6.35% |
| 2010-12-31 | €22.40 Million | +7.37% |
| 2009-12-31 | €20.87 Million | +9.68% |
| 2008-12-31 | €19.02 Million | -4.30% |
| 2007-12-31 | €19.88 Million | +1.99% |
| 2006-12-31 | €19.49 Million | +35.95% |
| 2005-12-31 | €14.34 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Clinica Baviera's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 420.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €40.20 Million | 41.48% |
| Common Stock | €1.63 Million | 1.68% |
| Other Comprehensive Income | €59.33 Million | 61.21% |
| Total Equity | €96.92 Million | 100.00% |
Clinica Baviera Competitors by Market Cap
The table below lists competitors of Clinica Baviera ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OLYFF
PINK:OLYFF
|
$110.79 Million |
|
Speed Tech
TWO:5457
|
$110.79 Million |
|
NH SPAC 2
KQ:206640
|
$110.88 Million |
|
National Aerospace Fasteners Corp
TW:3004
|
$110.90 Million |
|
Seoyon E Hwa Co Ltd
KO:200880
|
$110.76 Million |
|
Webzen Inc
KQ:069080
|
$110.68 Million |
|
AMTD Digital Inc.
NYSE:HKD
|
$110.65 Million |
|
Donglai Coating Technology (Shanghai) Co. Ltd. A
SHG:688129
|
$110.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Clinica Baviera's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 90,996,308 to 96,920,000, a change of 5,923,692 (6.5%).
- Net income of 40,205,000 contributed positively to equity growth.
- Dividend payments of 25,890,000 reduced retained earnings.
- Share repurchases of 10,240,000 reduced equity.
- New share issuances of 1,431,000 increased equity.
- Other comprehensive income increased equity by 11,042,431.
- Other factors decreased equity by 10,624,739.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €40.20 Million | +41.48% |
| Dividends Paid | €25.89 Million | -26.71% |
| Share Repurchases | €10.24 Million | -10.57% |
| Share Issuances | €1.43 Million | +1.48% |
| Other Comprehensive Income | €11.04 Million | +11.39% |
| Other Changes | €-10.62 Million | -10.96% |
| Total Change | €- | 6.51% |
Book Value vs Market Value Analysis
This analysis compares Clinica Baviera's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.31x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 108.30x to 8.31x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | €0.46 | €49.50 | x |
| 2006-12-31 | €1.19 | €49.50 | x |
| 2007-12-31 | €1.21 | €49.50 | x |
| 2008-12-31 | €1.17 | €49.50 | x |
| 2009-12-31 | €1.28 | €49.50 | x |
| 2010-12-31 | €1.38 | €49.50 | x |
| 2011-12-31 | €1.46 | €49.50 | x |
| 2012-12-31 | €1.31 | €49.50 | x |
| 2013-12-31 | €1.53 | €49.50 | x |
| 2014-12-31 | €1.22 | €49.50 | x |
| 2015-12-31 | €1.29 | €49.50 | x |
| 2016-12-31 | €1.13 | €49.50 | x |
| 2017-12-31 | €1.51 | €49.50 | x |
| 2018-12-31 | €1.75 | €49.50 | x |
| 2019-12-31 | €1.88 | €49.50 | x |
| 2020-12-31 | €2.73 | €49.50 | x |
| 2021-12-31 | €3.35 | €49.50 | x |
| 2022-12-31 | €4.13 | €49.50 | x |
| 2023-12-31 | €5.58 | €49.50 | x |
| 2024-12-31 | €5.95 | €49.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Clinica Baviera utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 41.48%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.31%
- • Asset Turnover: 1.24x
- • Equity Multiplier: 2.19x
- Recent ROE (41.48%) is above the historical average (0.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -261.38% | -44.66% | 1.44x | 4.06x | €-20.12 Million |
| 2006 | -136.01% | -41.40% | 1.46x | 2.24x | €-28.23 Million |
| 2007 | -120.54% | -30.31% | 1.73x | 2.30x | €-25.73 Million |
| 2008 | 35.44% | 7.69% | 1.37x | 3.36x | €4.86 Million |
| 2009 | 8.92% | 2.24% | 1.42x | 2.82x | €-225.74K |
| 2010 | 23.38% | 5.84% | 1.58x | 2.54x | €3.00 Million |
| 2011 | 22.78% | 5.77% | 1.62x | 2.44x | €3.03 Million |
| 2012 | -3.00% | -0.71% | 1.74x | 2.42x | €-2.78 Million |
| 2013 | 18.85% | 5.88% | 1.66x | 1.94x | €2.21 Million |
| 2014 | 20.07% | 4.83% | 1.68x | 2.46x | €2.00 Million |
| 2015 | 22.97% | 5.66% | 1.84x | 2.20x | €2.73 Million |
| 2016 | 42.94% | 8.68% | 1.96x | 2.53x | €6.09 Million |
| 2017 | 40.17% | 9.89% | 1.85x | 2.20x | €7.42 Million |
| 2018 | 41.80% | 10.90% | 1.96x | 1.96x | €9.06 Million |
| 2019 | 42.17% | 10.38% | 1.22x | 3.32x | €9.84 Million |
| 2020 | 31.76% | 11.53% | 1.01x | 2.72x | €9.68 Million |
| 2021 | 51.15% | 16.17% | 1.29x | 2.45x | €22.47 Million |
| 2022 | 44.77% | 15.19% | 1.32x | 2.23x | €23.41 Million |
| 2023 | 40.39% | 16.34% | 1.26x | 1.96x | €27.65 Million |
| 2024 | 41.48% | 15.31% | 1.24x | 2.19x | €30.51 Million |
Industry Comparison
This section compares Clinica Baviera's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $3,196,641
- Average return on equity (ROE) among peers: 3.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Clinica Baviera (CBAV) | €97.36 Million | -261.38% | 1.34x | $110.76 Million |
| Euroespes S.A. (EEP) | $4.57 Million | 2.31% | 1.05x | $3.02 Million |
| Pangaea Oncology S.A. (PANG) | $1.83 Million | 4.24% | 2.58x | $13.97 Million |